Phase 2/3Vertex Pharmaceuticals Incorporated/ A Phase 2/3 Adaptive, Double-blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of VX-147 in Subjects Aged 12 Years and Older With APOL1-mediated Proteinuric Kidney Disease (Sponsor: Vertex Pharmaceuticals)
ClinicalTrials.govNCT05312879
Phase 4Randomized, Double-blind, Placebo-controlled Phase 4 Clinical Trial to Evaluate the Long-term Safety and Efficacy of Avacopan in Subjects With Antineutrophil Cytoplasmic Antibody (ANCA)-associated Vasculitis (Sponsor: Amgen Inc.)
ClinicalTrials.govNCT06072482
An Open-label Extension Study Evaluating the Long-term Safety and Efficacy of Seralutinib Orally Inhaled for the Treatment of Pulmonary Arterial Hypertension (PAH)
ClinicalTrials.govNCT06274801Phase 3A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Seralutinib for the Treatment of Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD) Followed by a Long-Term Extension Evaluating Safety and Efficacy (Sponsor: Gossamer Bio)
ClinicalTrials.govNCT07181382
An Open-Label Prospective Multicenter study to evaluate Safety and Tolerability of Dry Powder Inhaled Treprostinil in Pulmonary Hypertension (Sponsor: Liquidia Corp)
ClinicalTrials.govNCT06129240
Phase 2b/3A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CLS300 (Clazakizumab) in Subjects with End Stage Kidney Disease Undergoing Dialysis (Sponsor: CSL Behring Inc.)
ClinicalTrials.govNCT05485961
Phase 3An Open-label, Multicenter, Randomized Phase 3 Study Evaluating the Efficacy and Safety of Felzartamab in Participants with Primary Membranous Nephropathy (Sponsor: Biogen Inc.)
ClinicalTrials.govNCT06962800
An open-label study to assess the efficacy and safety of TARPEYO® in adult patients with primary IgAN who have completed 9 months of TARPEYO® treatment in real world clinical practice (Sponsor: Calliditas Therapeutics)
ClinicalTrials.govNCT06712407
Phase 1bA Randomized, Placebo-Controlled, Phase 1b Clinical Study of the Safety, Tolerability, and Pharmacokinetics of MNKD-201 (Nintedanib Dry Powder Inhalation) in Patients with Idiopathic Pulmonary Fibrosis (Sponsor: Mannkind Corp)
ClinicalTrials.govNCT02999178
Prospective Sample Collection of Subjects for the development of multiple immunosuppressant therapeutics drug monitoring assays (Sponsor: RDI Trials)
End Stage Kidney Disease in California's Central Valley (Research Grant from Stanford University)